Proton DynamicArc improves selected breast target coverage but increases thyroid and skin exposure

In 40 breast and chest wall plans, DynamicArc improved coverage and robustness in challenging anatomies but increased thyroid dose and hotspots.

KEY POINTS

  • This retrospective single-center planning study compared proton DynamicArc with conventional IMPT in 40 patients, divided into four groups of ten: chest wall irradiation with tissue expanders, permanent implants, no reconstruction, and bilateral breast or chest wall irradiation. Most prescriptions were 50.4 Gy(RBE) in 28 fractions, with selected bilateral cases receiving 42.56 Gy(RBE) in 16 fractions.
  • DynamicArc plans used coplanar partial arcs of approximately 150–160°, whereas the original clinical IMPT plans used static fields. Both approaches employed Monte Carlo dose calculation, ±5 mm setup and ±3.5% range robustness criteria, and the same institutional proton beam model; however, optimization objectives differed between the two planning approaches.
  • In patients with tissue expanders, DynamicArc improved D95 for multiple targets, including the chest wall evaluation volume (49.36 versus 48.94 Gy[RBE]; q=0.048), axillary nodes (50.65 versus 50.07 Gy[RBE]; q=0.023), and supraclavicular nodes (50.69 versus 49.95 Gy[RBE]; q<0.006). Coverage posterior to the expander port improved, a clinically relevant challenge for static-field proton planning.
  • Robustness performance improved for selected targets, particularly with expanders and bilateral treatment. For example, achievement of the primary robustness goal increased from 40% with IMPT to 90% with DynamicArc for expander-cohort axillary targets, and from 0% to 70% for bilateral internal mammary nodal targets, although these were descriptive comparisons involving only ten patients per cohort.
  • Improved coverage came with increased dose heterogeneity. Target V105% increased in several nodal and chest wall structures, and some nodal targets exceeded the minor-deviation thresholds used in the BRE-009 trial planning framework. DynamicArc also increased thyroid mean dose in three ipsilateral cohorts and skin V95%, with thyroid increases remaining significant after multiple-comparison correction.
  • Heart mean dose, esophageal near-maximum dose and focal LAD hotspots were generally similar between techniques. Lung V20 was also largely unchanged, while median high-dose CTV LETd remained approximately 2.3–3.3 keV/µm across techniques; DynamicArc altered spatial dose–LET patterns but did not systematically increase median high-dose LET.
  • DynamicArc increased the number of spots and energy layers, resulting in longer estimated beam-on times across all cohorts, including approximately 12.3 additional minutes for bilateral irradiation. However, simulated total treatment times were comparable after accounting for IMPT field changes and room entry; the largest estimated advantage was 7.5 minutes saved in expander cases, not a directly measured clinical treatment-time reduction.

CLINICAL TAKEAWAY

Proton DynamicArc may offer planning advantages for complex breast and chest wall geometries, particularly where tissue expanders or multiple nodal targets make static-field coverage difficult. These benefits must be balanced against increased target hotspots, thyroid exposure and near-prescription skin dose, while treatment-time advantages remain workflow-dependent and require actual delivery validation.

SOURCE

International Journal of Radiation Oncology, Biology, Physics

Browse more research Suggest a correction